Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 12, 2013 - Issue 4
Submit an article Journal homepage
1,634
Views
64
CrossRef citations to date
0
Altmetric
Reviews

Drug-induced parkinsonism

José López-SendónHospital Ramón y Cajal, Servicio de Neurología, CIBERNED, Ctra de Colmenar Km 9,100, Madrid, 28034, Spain+0034 913368821; [email protected]
,
Maria A MenaHospital Ramón y Cajal, Neurobiologia, CIBERNED, Ctra de Colmenar Km 9,100, Madrid, 28034, Spain
&
Justo G de YébenesHospital Ramón y Cajal, Servicio de Neurología, CIBERNED, Ctra de Colmenar Km 9,100, Madrid, 28034, Spain+0034 913368821; [email protected]
Pages 487-496 | Published online: 31 Mar 2013

Citations (64)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Maham Sanawar, Uzma Saleem, Fareeha Anwar, Samra Nazir, Muhammad Furqan Akhtar, Bashir Ahmad & Tariq Ismail. (2022) Investigation of anti-Parkinson activity of dicyclomine . International Journal of Neuroscience 132:4, pages 338-351.
Read now
Pierre J Blanchet & Veronika Kivenko. (2016) Drug-induced parkinsonism: diagnosis and management. Journal of Parkinsonism and Restless Legs Syndrome 6, pages 83-91.
Read now
Dénes Zádori, Gábor Veres, Levente Szalárdy, Péter Klivényi & László Vécsei. (2015) Drug-induced movement disorders. Expert Opinion on Drug Safety 14:6, pages 877-890.
Read now

Articles from other publishers (61)

Thibault Viguier, Marie‐Sara Agier, Annie‐Pierre Jonville‐Béra, Bruno Giraudeau & Bérenger Largeau. (2023) Drug clustering to anticipate new aspects of drug safety profile: Application to gabapentinoids and other voltage‐gated calcium channel ligand drugs. British Journal of Clinical Pharmacology.
Crossref
Ziyang Ren, Yunhan Xu, Jinfang Sun, Yanqing Han, Lin An & Jufen Liu. (2023) Chronic diseases and multimorbidity patterns, their recent onset, and risk of new-onset Parkinson's disease and related functional degeneration in older adults: a prospective cohort study. eClinicalMedicine 65, pages 102265.
Crossref
Seulki Song, Jun Y Kim, Young Lee, Hyokeun Jeong, Seungyeon Kim & Eunkyung E Lee. (2023) Effects of defoliant exposure and medication use on the development of Parkinson’s disease in veterans. Age and Ageing 52:10.
Crossref
Axelle Dovonou, Cyril Bolduc, Victoria Soto Linan, Charles Gora, Modesto R. Peralta III & Martin Lévesque. (2023) Animal models of Parkinson’s disease: bridging the gap between disease hallmarks and research questions. Translational Neurodegeneration 12:1.
Crossref
Siin Kim & Hae Sun Suh. (2023) Treatment Changes and Prognoses in Patients with Incident Drug-Induced Parkinsonism Using a Korean Nationwide Healthcare Claims Database. Journal of Clinical Medicine 12:8, pages 2860.
Crossref
Soo Min Jeon, Yu Jin Lee & Jin-Won Kwon. (2023) Prevalence and causative drugs of drug-induced Parkinsonism in pediatric patients. European Child & Adolescent Psychiatry.
Crossref
Kairi Ri, Toshiki Fukasawa, Satomi Yoshida, Masato Takeuchi & Koji Kawakami. (2023) Risk of parkinsonism and related movement disorders with gabapentinoids or tramadol: A case‐crossover study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.
Crossref
Eunkyeong Choi, Siin Kim & Hae Sun Suh. (2022) Exploring the prevalence and characteristics of adverse drug events among older adults in South Korea using a national health insurance database. Frontiers in Pharmacology 13.
Crossref
Stefano Calzetti & Anna Negrotti. (2022) Permanent non-progressive cinnarizine and flunarizine-induced parkinsonism: An under-recognized tardive syndrome in the elderly?. Journal of the Neurological Sciences, pages 120526.
Crossref
Maira Ayaz, Fareeha Anwar, Uzma Saleem, Irum Shahzadi, Bashir Ahmad, Ali Mir & Tariq Ismail. (2022) Parkinsonism Attenuation by Antihistamines via Downregulating the Oxidative Stress, Histamine, and Inflammation. ACS Omega 7:17, pages 14772-14783.
Crossref
Kenichiro SatoYoshiki NiimiTatsuo ManoAtsushi IwataTakeshi Iwatsubo. (2022) Time to onset of drug-induced parkinsonism: Analysis using a large Japanese adverse event self-reporting database. BioScience Trends 16:2, pages 151-157.
Crossref
Ankush Garg & Sharmistha Sinha. (2022) Doxorubicin induced aggregation of α-synuclein: Insights into the mechanism of drug induced Parkinsonism. Colloids and Surfaces B: Biointerfaces 212, pages 112371.
Crossref
Hui Zhang, Wenjing Zhou & Donglan Zhang. (2022) Direct Medical Costs of Parkinson’s Disease in Southern China: A Cross-Sectional Study Based on Health Insurance Claims Data in Guangzhou City. International Journal of Environmental Research and Public Health 19:6, pages 3238.
Crossref
Yoon-Sang Oh, Sang-Won Yoo, Chul Hyoung Lyoo & Joong-Seok Kim. (2022) Decreased thalamic monoamine availability in drug-induced parkinsonism. Scientific Reports 12:1.
Crossref
Youngkwon Jo, Seungyeon Kim, Byoung Seok Ye, Euni Lee & Yun Mi Yu. (2022) Protective Effect of Renin-Angiotensin System Inhibitors on Parkinson’s Disease: A Nationwide Cohort Study. Frontiers in Pharmacology 13.
Crossref
Najmeh Nikmanesh, Ebrahim Moghimi Sarani, Samaneh Khazraei, Peyman Petramfar & Vahid Reza Ostovan. (2021) Diagnostic accuracy of brain stem auditory evoked response in distinguishing drug-induced parkinsonism from Parkinson'sdisease. Neurophysiologie Clinique 51:6, pages 524-532.
Crossref
Mark N. Warden, Susan Searles Nielsen, Alejandra Camacho-Soto, Roman Garnett & Brad A. Racette. (2021) A comparison of prediction approaches for identifying prodromal Parkinson disease. PLOS ONE 16:8, pages e0256592.
Crossref
Henrik Renner, Katharina J. Becker, Theresa E. Kagermeier, Martha Grabos, Farsam Eliat, Patrick Günther, Hans R. Schöler & Jan M. Bruder. (2021) Cell-Type-Specific High Throughput Toxicity Testing in Human Midbrain Organoids. Frontiers in Molecular Neuroscience 14.
Crossref
Kenichiro Sato, Tatsuo Mano, Atsushi Iwata & Tatsushi Toda. (2021) Disproportionality by sex in the prescription of drugs capable of inducing parkinsonism for the elderly: A survey using statistics of Japanese national health claims from 2014 to 2017. Neurology and Clinical Neuroscience 9:3, pages 211-217.
Crossref
Ditte Rudå, Gudmundur Einarsson, Anne Sofie Schott Andersen, Jannik Boll Matthiassen, Christoph U. Correll, Kristian Winge, Line K. H. Clemmensen, Rasmus R. Paulsen, Anne Katrine Pagsberg & Anders Fink-Jensen. (2021) Exploring Movement Impairments in Patients With Parkinson's Disease Using the Microsoft Kinect Sensor: A Feasibility Study. Frontiers in Neurology 11.
Crossref
Yoonjung Kwon, Yeojin Bang, Soung-Hee Moon, Aeri Kim & Hyun Jin Choi. (2020) Amitriptyline interferes with autophagy-mediated clearance of protein aggregates via inhibiting autophagosome maturation in neuronal cells. Cell Death & Disease 11:10.
Crossref
Seungyeon Kim, Yun Mi Yu, Jeongyoon Kwon, Kyeong Hye Jeong, Jeong Sang Lee & Euni Lee. (2020) Trimetazidine Use and the Risk of Parkinsonism: A Nationwide Population-Based Study. International Journal of Environmental Research and Public Health 17:19, pages 7256.
Crossref
Se Won Oh, Na-Young Shin, Uicheul Yoon, Intae Sin & Seung-Koo Lee. (2020) Shared functional neural substrates in Parkinson's disease and drug-induced parkinsonism: association with dopaminergic depletion. Scientific Reports 10:1.
Crossref
Abilash Muralidharan, Jawaria Rahman, Dipanjan Banerjee, Abdul Rub Hakim Mohammed & Bilal Haider Malik. (2020) Parkinsonism: A Rare Adverse Effect of Valproic Acid. Cureus.
Crossref
Anna Marielle B. Dy, Lorenzo Luis G. Limjoco & Roland Dominic G. Jamora. (2020) Trimetazidine-Induced Parkinsonism: A Systematic Review. Frontiers in Neurology 11.
Crossref
Kei Tachibana, Keita Matsuura, Akihiro Shindo, Hirofumi Matsuyama, Yuichiro Ii, Akira Taniguchi & Hidekazu Tomimoto. (2020) Symptomatic Characteristics of Parkinson's Disease Induced by Neuroleptic Drugs, Based on a Functional Neuroimaging Diagnosis. Internal Medicine 59:4, pages 485-490.
Crossref
Jamir Pitton Rissardo & Ana Letícia Fornari Caprara. (2020) Buspirone-associated Movement Disorder: A Literature Review. Prague Medical Report 121:1, pages 5-24.
Crossref
Tatiana Pacheco‐Paez, François Montastruc, Vanessa Rousseau, Leila Chebane, Maryse Lapeyre‐Mestre, Christel Renoux & Jean‐Louis Montastruc. (2019) Parkinsonism Associated with Gabapentinoid Drugs: A Pharmacoepidemiologic Study. Movement Disorders 35:1, pages 176-180.
Crossref
Sola Han, Siin Kim, Hyungtae Kim, Hae-Won Shin, Kyoung-Sae Na & Hae Sun Suh. (2019) Prevalence and incidence of Parkinson’s disease and drug-induced parkinsonism in Korea. BMC Public Health 19:1.
Crossref
Siin Kim & Hae Sun Suh. (2019) Current Status of Parkinsonism-Related Adverse Events and Associated Drugs in Korea. Journal of Patient Safety 15:4, pages e56-e59.
Crossref
Siin Kim, Sang-Myung Cheon & Hae Sun Suh. (2019) Association Between Drug Exposure and Occurrence of Parkinsonism in Korea: A Population-Based Case-Control Study. Annals of Pharmacotherapy 53:11, pages 1102-1110.
Crossref
Hannah O'Brien, Fiona Kiely, Aileen Barry & Sarah Meaney. (2019) Cross-sectional examination of extrapyramidal side effects in a specialist palliative care inpatient unit. BMJ Supportive & Palliative Care 9:3, pages 271-273.
Crossref
Ho Sang Yoo, Yong Wook Kim & Na Young Kim. (2019) Drug-Induced Parkinsonism Manifesting as Gait Freezing in a Patient With Traumatic Brain Injury: A Case Report. Clinical Neuropharmacology 42:3, pages 94-96.
Crossref
Ranbir Singh. (2019) Tramadol-induced parkinsonism: a case report of a 75-year-old woman. Journal of Basic and Clinical Physiology and Pharmacology 30:2, pages 275-278.
Crossref
Helene G. van der Meer, Katja Taxis, Martina Teichert, Fabiënne Griens, Lisa G. Pont & Hans Wouters. (2019) Anticholinergic and sedative medication use in older community-dwelling people: A national population study in the Netherlands. Pharmacoepidemiology and Drug Safety 28:3, pages 315-321.
Crossref
Jing-si Zhou, Zhou Zhu, Feng Wu, Ying Zhou, Rui Sheng, Jun-chao Wu & Zheng-hong Qin. (2018) NADPH ameliorates MPTP-induced dopaminergic neurodegeneration through inhibiting p38MAPK activation. Acta Pharmacologica Sinica 40:2, pages 180-191.
Crossref
Chien-Hsu Lai, Yi-Chun Yeh & Yen-Yu Chen. (2019) Metoclopramide as a prokinetic agent for diabetic gastroparesis: revisiting the risk of Parkinsonism. Therapeutic Advances in Drug Safety 10, pages 204209861985400.
Crossref
Pierre R. Burkhard. 2019. Therapy of Movement Disorders. Therapy of Movement Disorders 291 295 .
Lauren Charlot, Rory Sheehan & Angela Hassiotis. 2019. Handbook of Intellectual Disabilities. Handbook of Intellectual Disabilities 661 681 .
Verónica Alejandra Cáceres-Chávez, Ricardo Hernández-Martínez, Jesús Pérez-Ortega, Marco Arieli Herrera-Valdez, Jose J. Aceves, Elvira Galarraga & José Bargas. (2018) Acute dopamine receptor blockade in substantia nigra pars reticulata: a possible model for drug-induced Parkinsonism. Journal of Neurophysiology 120:6, pages 2922-2938.
Crossref
Houman Homayoun. (2018) Parkinson Disease. Annals of Internal Medicine 169:5, pages ITC33-ITC48.
Crossref
Shin-Chia Tsai, Shiow-Yunn Sheu, Li-Nien Chien, Hsin-Chien Lee, Eunice Jia-Shiow Yuan & Rey-Yue Yuan. (2018) High exposure compared with standard exposure to metoclopramide associated with a higher risk of parkinsonism: a nationwide population-based cohort study. British Journal of Clinical Pharmacology 84:9, pages 2000-2009.
Crossref
Erik BootNancy J. ButcherSean UdowConnie MarrasKin Y. MokSatoshi KanekoMatthew J. BarrettPaolo PronteraBrian D. BermanMario MasellisBoris DufournetKarine NguyenPerrine CharlesEugénie MutezTeodor DanailaAurélia JacquetteOlivier ColinSophie DrapierMichel BorgAnia M. FiksinskiElfi VergaelenAnn SwillenAnnick VogelsAnnika PlateClaudia PerandonesThomas GasserKristien ClerinxFrédéric BourdainKelly MillsNigel M. WilliamsNicholas W. WoodJan BooijAnthony E. LangAnne S. BassettNicola Tambasco, Gabriela M Repetto, Rosemarie Fritsch, Barber M Tinselboer, Jacob AS Vorstman, Luis A Pellene, Stephen G Reich, Claudia Schulte & Annet Dekker. (2018) Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. Neurology 90:23.
Crossref
Julia M. Lappin, Shane Darke & Michael Farrell. (2018) Methamphetamine use and future risk for Parkinson’s disease: Evidence and clinical implications. Drug and Alcohol Dependence 187, pages 134-140.
Crossref
Seyed‐Mohammad Fereshtehnejad, Benjamin K. Dawson, Amelie Pelletier, Jacques Y. Montplaisir & Ronald B. Postuma. (2018) Long Lag Between Drug‐induced Parkinsonism and Idiopathic Parkinson's Disease in Idiopathic REM Sleep Behavior Disorder. Movement Disorders Clinical Practice 5:2, pages 203-205.
Crossref
Lydia E. Pieters, P. Roberto Bakker & Peter N. van Harten. (2018) Asymmetric Drug-Induced Parkinsonism and Psychopathology: A Prospective Naturalistic Study in Long-Stay Psychiatric Patients. Frontiers in Psychiatry 9.
Crossref
Vesselin Z. Miloushev & Ronald G. Blasberg. 2018. Imaging and Metabolism. Imaging and Metabolism 199 222 .
Eun-ji Kim, Ho-joon Song, Hyun-ho Kim, Yang-hee Han & Jung-tae Leem. (2017) A Case Report of Drug-Induced Parkinsonism Treated with Jodeung-san and Electro-acupuncture at GB34. The Journal of Internal Korean Medicine 38:5, pages 600-609.
Crossref
Daniela Frosini, Mirco Cosottini, Duccio Volterrani & Roberto Ceravolo. (2017) Neuroimaging in Parkinson's disease: focus on substantia nigra and nigro-striatal projection. Current Opinion in Neurology 30:4, pages 416-426.
Crossref
Renato P. Munhoz, Delcio Bertucci Filho & H?lio A. G. Teive. (2016) Not all drug-induced parkinsonism are the same: the effect of drug class on motor phenotype. Neurological Sciences 38:2, pages 319-324.
Crossref
Joong-Seok KimDong-Woo RyuJu-Hee OhYang-Hyun LeeSung-Jin ParkKipyung JeonJong-Yun LeeSeong Hee HoJungmin SoJin Hee ImKwang-Soo Lee. (2017) Cardiovascular Autonomic Dysfunction in Patients with Drug-Induced Parkinsonism. Journal of Clinical Neurology 13:1, pages 15.
Crossref
Jorik Nonnekes, Monique H.M. Timmer, Nienke M. de Vries, Olivier Rascol, Rick C. Helmich & Bastiaan R. Bloem. (2016) Unmasking levodopa resistance in Parkinson's disease. Movement Disorders 31:11, pages 1602-1609.
Crossref
Jose L. L?pez-Send?n Moreno, Araceli Alonso-C?novas, Javier Buis?n Catevilla, Nuria Garc?a Barrag?n, I?igo Corral Corral, Alicia de Felipe Mimbrera, Mar?a Consuelo Matute Lozano, Jaime Masjuan Vallejo & Juan Carlos Mart?nez-Castrillo. (2016) Substantia Nigra Echogenicity Predicts Response to Drug Withdrawal in Suspected Drug-Induced Parkinsonism. Movement Disorders Clinical Practice 3:3, pages 268-274.
Crossref
Umar A. Shuaib, Ali H. Rajput, Christopher A. Robinson & Alex Rajput. (2015) Neuroleptic‐induced P arkinsonism: C linicopathological study . Movement Disorders 31:3, pages 360-365.
Crossref
Dilan Athauda, Robert Batley & Catherine Ellis. (2014) Clinically silent idiopathic Parkinson’s disease unmasked by valproate use: a brief report. Aging Clinical and Experimental Research 27:3, pages 387-390.
Crossref
Tejal Patel & Feng Chang. (2015) Practice recommendations for Parkinson’s disease. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada 148:3, pages 142-149.
Crossref
Hyun Jung Ahn, Woo-Kyoung Yoo, Jaeseol Park, Hyeo-Il Ma & Yun Joong Kim. (2015) Cognitive Dysfunction in Drug-induced Parkinsonism Caused by Prokinetics and Antiemetics. Journal of Korean Medical Science 30:9, pages 1328.
Crossref
Francesco Brigo, Roberto Erro, Antonio Marangi, Kailash Bhatia & Michele Tinazzi. (2014) Differentiating drug-induced parkinsonism from Parkinson's disease: An update on non-motor symptoms and investigations. Parkinsonism & Related Disorders 20:8, pages 808-814.
Crossref
Manuel Menéndez-González, Francisco Tavares, Nahla Zeidan, José M. Salas-Pacheco & Oscar Arias-Carrión. (2014) Diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT: a clinical follow up study. Frontiers in Aging Neuroscience 6.
Crossref
Pierre R. Burkhard. (2014) Acute and subacute drug-induced movement disorders. Parkinsonism & Related Disorders 20, pages S108-S112.
Crossref
Santiago Perez-Lloret, Jean-Louis Montastruc & Olivier Rascol. 2014. Movement Disorders in Dementias. Movement Disorders in Dementias 87 115 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.